New hope for rare vascular conditions: phase 3 drug trial launches
NCT ID NCT07285005
First seen Jan 07, 2026 · Last updated May 17, 2026 · Updated 17 times
Summary
This study tests an experimental drug called KP-001 in people aged 2 and older with certain blood vessel or lymphatic malformations (including KTS/CLOVES syndrome). The goal is to see if the drug can shrink these abnormal growths and improve symptoms compared to a placebo. Participants will first receive either the drug or a placebo for 24 weeks, then everyone will receive the drug for another 28 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHATIC MALFORMATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.